Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report
Ficheros
Identificadores
Compartir
Metadatos
Mostrar el registro completo del ítemAutor
Bustos, Antonio; Selvi Sabater, Pablo; Benlloch, María; Drehmer, Eraci; López-Rodríguez, María Mar; [et al.]Fecha
2021-01-24Resumen
Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk test (10MWT), nine-hole peg test (9HPT) and handgrip strength measurement using a handheld Jamar dynamometer. Results: Regarding muscular and motor functions associated with higher inflammation and oxidation, improvements only observed in the woman in all analysed parameters (both biochemical and cl...
Palabra/s clave
Charcot-Marie-Tooth disease type 2
epigallocatechin gallate
IL-6
motor activity
paraoxonase 1